Protective effects of cilnidipine against hyperuricemia-related renal and vascular injury

2016 Fiscal Year Final Research Report

• Project/Area Number: 25460662
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Applied pharmacology
• Research Institution: Kyoto Pharmaceutical University
• Principal Investigator: Toba Hiroe 京都薬科大学, 薬学部, 助教 (90351270)
• Project Period (FY): 2013-04-01 – 2017-03-31
• Keywords: 高尿酸血症

Outline of Final Research Achievements

This study investigated whether hyperuricemia could induce vascular and renal dysfunction. Administration of an uricase inhibitor potassium oxonate (1500mg/kg/day) increased plasma uric acid levels in uninephrectomized rats (2.7±0.1mg/dL vs. 2.0±0.1mg/dL, p<0.05）. In the hyperuricemia group, urinary protein excretion increased (11±1.2mg/day vs. 7±0.5mg/day, p<0.05) and endothelium-dependent relaxation of the aorta was impaired compared to the vehicle group, whereas there were no significant differences in blood pressure. Cilnidipine had not effect on blood pressure, but decreased plasma uric acid and proteinuria and improved vasodilatory response. These results suggest that the increase in plasma uric acid could be a risk factor for renal and vascular injury. Cilnidipine might be beneficial against renal and vascular dysfunction which relates to hyperuricemia.

Free Research Field

薬理学